Results 181 to 190 of about 130,782 (308)

Safety and Efficacy of MEK Inhibitor Treatment for Gastric Precancerous Lesions. [PDF]

Gastroenterology
Goldenring JR, Jang B, Gotoda T, Yamaguchi N, Choi E, Nomura S, Gastric Precancer Working Group.   +6 more
europepmc   +1 more source

A phase 1 dose-escalation and expansion study of binimetinib (MEK162), a potent and selective oral MEK1/2 inhibitor [PDF]

, 2017
et al,, Tan, Benjamin R
core   +2 more sources

TANC1::HTRA1 fusion in schwannomas

Brain Pathology, EarlyView.
Ilay Caliskan, Kanish Mirchia, Walter Patrick Devine, Melike Pekmezci   +3 more
wiley   +1 more source

Neoadjuvant therapy in skin cancer: current evidence and future perspectives

JDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Summary The development of immune checkpoint inhibitors and targeted therapies has fundamentally changed the treatment of cutaneous malignancies, especially in squamous cell carcinoma, melanoma, and Merkel cell carcinoma. The latest neoadjuvant approaches have shown promising results in locally advanced stages.
Lea Daniello, Johannes Kleemann, Bastian Schilling   +2 more
wiley   +1 more source

EGFR-mutant transformed small cell lung cancer harbors intratumoral heterogeneity targetable with MEK inhibitor combination therapy. [PDF]

JCI Insight
Ogino A, Vajdi A, Mu XJ, Mahadevan NR, Ngo K, Booker MA, Cejas P, Okoro JJ, Xu M, Springer BF, Eschle BK, Messier CM, Wang S, Syamala S, Tamen RM, Adeni AE, Chambers ES, Canadas I, Thai T, Christensen CL, Xu C, Lizotte PH, Oxnard GR, Watanabe H, Long HW, Gokhale PC, Paweletz CP, Sholl LM, Oser MG, Barbie DA, Tolstorukov MY, Jänne PA.   +31 more
europepmc   +1 more source

MEK Inhibitor SHR 7390 [PDF]

, 2020
openaire   +1 more source

Growth differentiation factor 15 mitigates lipotoxic steatosis by preserving mitochondrial morphodynamics and augmenting fatty acid oxidation in hepatocytes and liver organoids

Diabetes, Obesity and Metabolism, EarlyView.
Abstract Aims Growth differentiation factor 15 (GDF15) has emerged as a promising metabolic regulator with hepatoprotective properties in metabolic dysfunction‐associated steatotic liver disease (MASLD), yet its underlying mechanisms remain elusive.
Jia Li, Qi Zhou, Mengmeng Xia, Yakun Li, Junyu Wang, Manon Buist‐Homan, Vincent E. de Meijer, Hans Blokzijl, Klaas Nico Faber, Han Moshage   +9 more
wiley   +1 more source

Tumor heterogeneity underlies clinical outcome and MEK inhibitor response in somatic NF1-mutant glioblastoma. [PDF]

JCI Insight
Pan S, Mirchia K, Payne E, Liu SJ, Al-Adli N, Peeran Z, Shukla P, Young JS, Gupta R, Wu J, Pak J, Ozawa T, Na B, Reddy AT, Braunstein SE, Phillips JJ, Chang S, Solomon DA, Perry A, Raleigh DR, Berger MS, Abate AR, Vasudevan HN.   +22 more
europepmc   +1 more source

MEK Inhibitor GDC-0623 [PDF]

, 2020
openaire   +1 more source

Extracellular matrix and proteolysis: mechanisms driving irreversible changes and shaping cell behavior

The FEBS Journal, EarlyView.
Irreversible ECM proteolysis by remodeling enzymes shapes development, homeostasis, and disease. ECM‐degrading proteases display cell specificity and are governed by shared mechanisms, exhibiting functional redundancy in generating matrikines, growth factors, and cytokines.
Inna Solomonov, Orit Kollet, Irit Sagi
wiley   +1 more source